Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDCL3 pseudogene 2 (PDCL3P2) is a pseudogene derived from the PDCL3 gene, which encodes phosducin-like protein 3, a molecular chaperone involved in G protein signaling, cytoskeletal protein folding, and angiogenesis[1][2][3][4]. Pseudogenes are genomic sequences similar to known genes but typically lack biological function due to mutations or truncations; however, some pseudogenes may act as noncoding RNAs affecting gene expression. Although the PDCL3 gene and other related pseudogenes (such as PDCL3P4) have shown regulatory impact and disease relevance, PDCL3P2 itself is not reported as functional, has no known protein product, and is not considered a therapeutic target. Structured information for PDCL3P2 is largely missing; any functional or clinical relevance remains speculative. PDCL3P2 is not a receptor, enzyme, or transporter, and most pseudogenes, including PDCL3P2, are not protein-coding, though some act via RNA mechanisms. Structured annotation for PDCL3P2 is not available in major genomic databases, and it is not listed among clinically relevant biomarker or drug-interaction targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PDCL3 pseudogene 2 (PDCL3P2).